68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT
…, E Von Guggenberg, R Bale, IJ Virgolini - Journal of nuclear …, 2007 - Soc Nuclear Med
The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 68
Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid-d-Phe 1 -Tyr …
Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid-d-Phe 1 -Tyr …
European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of …
…, AT Scott, S Elojeimy, D Rubello, IJ Virgolini… - European journal of …, 2019 - Springer
Purpose Diverse radionuclide imaging techniques are available for the diagnosis, staging,
and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to …
and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to …
68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
…, P Castellucci, S Fanti, IJ Virgolini - European journal of …, 2015 - Springer
Purpose To assess the association between PSA levels, PSA kinetics and other factors and
a pathological 68 Ga-PSMA PET/CT scan in patients with recurrent prostate cancer (rPCa) …
a pathological 68 Ga-PSMA PET/CT scan in patients with recurrent prostate cancer (rPCa) …
[18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma
…, M McCoy, G Göbel, C la Fougère, IJ Virgolini… - Neuro …, 2013 - academic.oup.com
Background To assess the sensitivity and specificity of [ 18 F]-fluoro-ethyl-l-tyrosine ( 18 F-FET)
PET in brain tumors and various non-neoplastic neurologic diseases. Methods We …
PET in brain tumors and various non-neoplastic neurologic diseases. Methods We …
68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor–mediated radionuclide therapy
…, C Uprimny, P Kovacs, R Bale, IJ Virgolini - Journal of Nuclear …, 2009 - Soc Nuclear Med
68 Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid-d-Phe
1 -Tyr 3 -octreotide (DOTA-TOC) PET has proven its usefulness in the diagnosis of patients …
1 -Tyr 3 -octreotide (DOTA-TOC) PET has proven its usefulness in the diagnosis of patients …
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma
…, H Kostron, A Muigg, IJ Virgolini… - Journal of Nuclear …, 2011 - Soc Nuclear Med
The objective of this study was to compare MRI response assessment with metabolic O-(2-
18 F-fluoroethyl)-L-tyrosine ( 18 F-FET) PET response evaluation during antiangiogenic …
18 F-fluoroethyl)-L-tyrosine ( 18 F-FET) PET response evaluation during antiangiogenic …
Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC
…, G Stockhammer, IJ Virgolini - Journal of Nuclear …, 2010 - Soc Nuclear Med
The treatment of patients with high-grade malignant glioma still represents an unsolved clinical
problem. We report the treatment of 3 patients who had World Health Organization grade …
problem. We report the treatment of 3 patients who had World Health Organization grade …
Twelve-year follow-up after peptide receptor radionuclide therapy
…, B Nilica, B Kaiser, IJ Virgolini - Journal of Nuclear …, 2019 - Soc Nuclear Med
Peptide receptor radionuclide therapy (PRRT) has been used for more than 20 y as a systemic
treatment approach in inoperable or metastatic somatostatin receptor–positive tumors. …
treatment approach in inoperable or metastatic somatostatin receptor–positive tumors. …
68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient
…, C Decristoforo, W Horninger, IJ Virgolini - European journal of …, 2015 - Springer
Recent reports suggest that 223Ra prolongs survival in prostate cancer patients [1]. Bone
scintigraphy is considered the gold standard in the assessment of osseous metastatic disease …
scintigraphy is considered the gold standard in the assessment of osseous metastatic disease …
11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer
…, R Bonfiglioli, S Costa, IJ Virgolini… - Clinical nuclear …, 2015 - journals.lww.com
Aim The aim of this study was to compare 11 C-choline PET/CT, prostate-specific antigen (PSA),
PSA kinetics, and 11 C-choline uptake in recurrent metastatic prostate cancer patients …
PSA kinetics, and 11 C-choline uptake in recurrent metastatic prostate cancer patients …